Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACR | P10323 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263131 | 0.86 | HPGD (0.52) | ACRMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL4908614 | 0.78 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL1686347 | 0.77 | POLB (0.66) | ACRMAPTHPGDALDH1A1POLB | |
| SCHEMBL28409037 | 0.76 | ACR (0.65) | ACRMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL28411916 | 0.75 | ACR (0.62) | ACRMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL4909172 | 0.75 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL29197994 | 0.74 | ACR (0.60) | ACRMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL1686327 | 0.72 | NOTUM (0.73) | ACRMAPTHPGDALDH1A1POLB | |
| SCHEMBL1686391 | 0.72 | TP53 (0.62) | ACRMAPTMEN1KMT2APOLB | |
| SCHEMBL1686476 | 0.72 | MAPT (0.72) | ACRMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | ACR 3310/4885MAPT 2515/4885HPGD 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.